LifeMD (LFMD) Cash & Equivalents (2012 - 2025)

LifeMD (LFMD) has reported Cash & Equivalents for 14 consecutive years, with $36.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 5.13% year-over-year to $36.8 million; the trailing twelve-month figure through Dec 2025 stood at $36.8 million (up 5.13% YoY), and the FY2025 full-year result was $36.8 million, up 5.13% from the prior year.
• Cash & Equivalents grew to $36.8 million in Q4 2025 per LFMD's latest filing, from $23.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q4 2021 and bottomed at $4.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $23.7 million across 5 years, with a median of $24.4 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents soared 5080.48% in 2021, then sank 90.42% in 2022.
• Over 5 years, Cash & Equivalents stood at $41.3 million in 2021, then tumbled by 90.42% to $4.0 million in 2022, then jumped by 737.26% to $33.1 million in 2023, then climbed by 5.61% to $35.0 million in 2024, then gained by 5.13% to $36.8 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $36.8 million, $23.8 million, and $36.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.